152 related articles for article (PubMed ID: 25700565)
1. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Gallina A; Bianchi M; Gandaglia G; Cucchiara V; Suardi N; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):750-3. PubMed ID: 25700565
[TBL] [Abstract][Full Text] [Related]
2. Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
Loeb S; Schlomm T; Stattin P
Eur Urol; 2015 Nov; 68(5):754-5. PubMed ID: 26238432
[No Abstract] [Full Text] [Related]
3. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
5. Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.
Wu Y; Qu X; Wang Y; Xia J; Gu Y; Qian Q; Hong Y
Andrologia; 2019 Mar; 51(2):e13198. PubMed ID: 30443968
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Chung JW; Kim JW; Ha YS; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim TH
Urol J; 2019 Jun; 16(3):255-259. PubMed ID: 31204438
[TBL] [Abstract][Full Text] [Related]
9. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
[TBL] [Abstract][Full Text] [Related]
11. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
12. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
Fode M; Østergren PB; Jensen CFS; Jakobsen H; Sønksen J
Scand J Urol; 2018 Apr; 52(2):108-110. PubMed ID: 29057723
[TBL] [Abstract][Full Text] [Related]
14. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
[TBL] [Abstract][Full Text] [Related]
15. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
16. Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
Knipper S; Sadat-Khonsari M; Boehm K; Mandel P; Budäus L; Steuber T; Maurer T; Heinzer H; Schwarz R; Sauter G; Tilki D; Huland H; Graefen M
Clin Genitourin Cancer; 2020 Apr; 18(2):e112-e121. PubMed ID: 31648965
[TBL] [Abstract][Full Text] [Related]
17. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.
Boehm K; Beyer B; Tennstedt P; Schiffmann J; Budaeus L; Haese A; Graefen M; Schlomm T; Heinzer H; Salomon G
World J Urol; 2015 Jun; 33(6):801-6. PubMed ID: 24989847
[TBL] [Abstract][Full Text] [Related]
18. Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.
Gandaglia G; Albersen M; Suardi N; Gallina A; Abdollah F; Castiglione F; Capitanio U; Salonia A; Rigatti P; Hedlund P; Montorsi F; Briganti A
Int J Urol; 2013 Apr; 20(4):413-9. PubMed ID: 22970988
[TBL] [Abstract][Full Text] [Related]
19. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
20. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
